Equillium EQ 深 滬
等待開盤 10-28 09:30:00 美东时间
1.36
+0.110
+8.80%
華盛通- 最 高1.39
- 今 開1.26
- 成交量 34.57万股
- 最 低 1.23
- 昨 收 1.25
- 總市值 8623.50万
- 52周最高 3.54
- 市盈率 靜 --
- 換手率 0.55%
- 52周最低 0.7562
- 委 比 9.91%
- 總股本 6340.81万
- 歷史最高 27.05
- 量 比 0.84
- 振 幅 12.80%
- 歷史最低 0.27
- 每 手 1
- 風險率 0.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Equillium收涨1.63%，成交额23.87万美元
10月27日，Equillium（EQ）收涨1.63%，报1.25美元，成交额23.87万美元，市值7925.97万美元。 行情数据 • 开盘价：1.2美元 ...
10-27 07:10
Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases
Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that the first subject has been dosed in Australia in its Phase 1 clinical trial of EQ504, an investigational oral, colon-targeted aryl hydrocarbo...
10-26 20:31
Equillium收跌9.85%，成交额58.46万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:15
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6
Leerink Partners analyst Will Soghikian assumes Equillium (NASDAQ:EQ) with a Outperform rating and announces Price Target of $6.
10-12 20:29
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
Equillium announced regulatory approval for its Phase 1 trial of EQ504 in Australia, aiming to begin dosing healthy participants by early November 2026. The randomized, double-blind, placebo-controlled study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of EQ504. EQ504, a potent AhR modulator, targets autoimmune and inflammatory disorders, particularly ulcerative colitis, by reducing inflammation and promoting mucosal h...
10-05 20:05
Equillium Announces Poster Presentations at the 7th International AHR Conference
<p>Equillium announced new preclinical data on EQ504, highlighting its effects on epithelial barrier repair and immune regulation. Presented at the 7th International AHR Conference, the findings demonstrate EQ504's potential for treating ulcerative colitis through selective AhR modulation. The studies, titled "Selective AhR Activation Suppresses Epithelial Chemokine Production and Promotes Barrier Repair Responses in Translational Models of Ulcer...
09-29 20:05
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target
Roth Capital analyst Adam Walsh reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $12 price target.
09-05 01:46
Equillium shares are trading higher after the company reported better-than-expected Q2 EPS results.
Equillium shares are trading higher after the company reported better-than-expected Q2 EPS results.
08-15 02:40
Analysts Are Bullish on These Healthcare Stocks: PolyPid (PYPD), Equillium (EQ)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-14 10:30
